First patient enrolled into phase I/II clinical trial of NY-ESO-1・siTCR　gene therapy against synovial sarcoma in Japan

First patient enrolled into phase I/II clinical trial of NY-ESO-1・siTCR　gene therapy against synovial sarcoma in Japan

Kusatsu/Shiga, Japan — January 17, 2018 — Takara Bio Inc. (Takara Bio), today announced that the first patient with synovial sarcoma has been enrolled into NY-ESO-1・siTCR gene therapy (TBI-1301) phase I/II clinical trial in Japan on January 15-16, 2018.
 
In the clinical trial, the gene of TCR which recognizes NY-ESO-1 antigen, a tumor antigen, is transferred ex-vivo to lymphocytes of patients, and the gene-modified lymphocytes are infused back to the patients. The patients will be monitored for safety and efficacy. The Takara Bio’s method for gene transduction, T-cell expansion methods using RetroNectin^®, and Takara Bio’s original retroviral vectors for siTCR transduction will be used during the cell processing for the clinical trial. NY-ESO-1・siTCR gene transduced lymphocytes manufactured at Center for Gene and Cell Therapy (Kusatsu, Shiga), Takara Bio’s facility, will be used.
 
Takara Bio attempts to achieve the early-approval utilizing the conditional and term-limited approval system for regenerative medicine under The Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical devices. Takara Bio aims to commercialize the NY-ESO-1・siTCR gene therapy in the fiscal year 2020.
 

Reference
“Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of NY-ESO-1・siTCR gene therapy in Japan”
– Our news release January 24, 2017 http://www.takara-bio.com/release/?p=599

This article is translated from press release in Japanese for your convenience.

Forward-Looking Statements
Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and product strategies, decline in selling power of the Company’s existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.